Ren Xiaoyan, Wu Wenjuan, Li Qiufan, Li Wen, Wang Xujuan, Wang Gang
Department of Gynecological Oncology, Sichuan Provincial Women's and Children's Hospital/The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China.
Front Endocrinol (Lausanne). 2024 Dec 11;15:1464959. doi: 10.3389/fendo.2024.1464959. eCollection 2024.
To investigate various supplements that improve insulin resistance, hormonal status, and oxidative stress in overweight or obese women with polycystic ovarian syndrome (PCOS).
A literature search was conducted on four different databases, which led to the discovery of twenty - five randomized controlled trials (RCTs). These RCTs evaluated the efficacy of various supplements in improving insulin resistance (IR), hormonal status, and oxidative stress among overweight or obese women diagnosed with PCOS. Subsequently, data extraction and analysis were carried out to determine the quality of the study's methodological design and the potential for bias. Moreover, a meta-analysis was performed using the data from the RCTs.
A total of 25 RCTs were carried out, and 1636 women were enrolled. All participants were overweight or obese. The standardized mean differences (SMD) were as follows: For fasting plasma glucose (FPG), it was -0.34 (95% confidence interval [CI], -0.49 to -0.19, p = 0.123, I = 30.8%); for insulin, it was -0.67 (95% CI, -0.83 to -0.52, p = 0.208, I = 24%); for fasting insulin (FI), it was -0.26 (95% CI, -0.52 to -0.00, p = 0.269, I = 21.9%); for homeostatic model assessment-insulin resistance index (HOMA-IR), it was -0.59 (95% CI, -0.73 to -0.45, p = 0.015, I = 48.7%); for homoeostatic model assessment beta - cell function (HOMA-B), it was -0.51 (95% CI, -0.75 to -0.27, p = 0.547, I = 0%); for quantitative insulin sensitivity check index (QUICKI), it was 0.94 (95% CI, 0.76 to -1.12, p = 0.191, I = 27.5%); for total testosterone, it was -0.61 (95% CI, -1.14 to -0.09, p = 0.00, I = 78.5%); for testosterone, it was -0.38 (95% CI, -0.86 to 0.10, p = 0.03, I = 71.5%); for follicle - stimulating hormone (FSH), it was 0.16 (95% CI, -0.08 to 0.40, p = 0.470, I = 0%); for luteinizing hormone (LH), it was -0.56 (95% CI, -1.32 to 0.20, p = 0.000, I = 91.1%); for sex hormone - binding globulin (SHBG), it was 0.35 (95% CI, 0.02 to 0.69, p = 0.000, I = 78%); for dehydroepiandrosterone (DHEAS), it was -0.27 (95% CI, -0.76 to 0.21, p = 0.001, I = 78.7%); for plasma total antioxidant capacity (TAC), it was 0.87 (95% CI, 0.45 to 1.30, p = 0.004, I = 71.3%); for plasma malondialdehyde (MDA), it was -0.57 (95% CI, -0.79 to -0.36, p = 0.992, I = 0.0%).
This study's findings indicate that, in comparison with a placebo, supplements have a favorable effect on IR, hormonal functions, and oxidative stress in PCOS. Nevertheless, it is crucial to note that the above-drawn conclusions need to be verified by more high-quality studies, given the limitations regarding the number and quality of the included studies.
研究各类补充剂对超重或肥胖的多囊卵巢综合征(PCOS)女性胰岛素抵抗、激素状态及氧化应激的改善作用。
在四个不同数据库进行文献检索,共发现25项随机对照试验(RCT)。这些RCT评估了各类补充剂对超重或肥胖且诊断为PCOS的女性改善胰岛素抵抗(IR)、激素状态及氧化应激的疗效。随后进行数据提取与分析,以确定研究方法设计的质量及偏倚可能性。此外,利用RCT数据进行荟萃分析。
共开展25项RCT,纳入1636名女性。所有参与者均超重或肥胖。标准化均数差(SMD)如下:空腹血糖(FPG)为-0.34(95%置信区间[CI],-0.49至-0.19,p = 0.123,I = 30.8%);胰岛素为-0.67(95% CI,-0.83至-0.52,p = 0.208,I = 24%);空腹胰岛素(FI)为-0.26(95% CI,-0.52至-0.00,p = 0.269,I = 21.9%);稳态模型评估胰岛素抵抗指数(HOMA-IR)为-0.59(95% CI,-0.73至-0.45,p = 0.015,I = 48.7%);稳态模型评估β细胞功能(HOMA-B)为-0.51(95% CI,-0.75至-0.27,p = 0.547,I = 0%);定量胰岛素敏感性检查指数(QUICKI)为0.94(95% CI,0.76至-1.12,p = 0.191,I = 27.5%);总睾酮为-0.61(95% CI,-1.14至-0.09,p = 0.00,I = 78.5%);睾酮为-0.38(95% CI,-0.86至0.10,p = 0.03,I = 71.5%);促卵泡激素(FSH)为0.16(95% CI,-0.08至0.40,p = 0.470,I = 0%);促黄体生成素(LH)为-0.56(95% CI,-1.32至0.20,p = 0.000,I = 91.1%);性激素结合球蛋白(SHBG)为0.35(95% CI,0.02至0.69,p = 0.000,I = 78%);脱氢表雄酮(DHEAS)为-0.27(95% CI,-0.76至0.21,p = 0.001,I = 78.7%);血浆总抗氧化能力(TAC)为0.87(95% CI,0.45至1.30,p = 0.004,I = 71.3%);血浆丙二醛(MDA)为-0.57(95% CI,-0.79至-0.36,p = 0.992,I = 0.0%)。
本研究结果表明,与安慰剂相比,补充剂对PCOS患者的胰岛素抵抗、激素功能及氧化应激有有益作用。然而,鉴于纳入研究的数量和质量存在局限性,上述结论需更多高质量研究加以验证。